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xercise Training and
yocardial Energetics in
atients With Heart Failure
hen More Is Less*
oward J. Eisen, MD, FACC
hiladelphia, Pennsylvania
eart failure is the major cause of morbidity and mortality
n the developed world, with over 5 million people afflicted
n the U.S. alone (1). From 30% to 40% of patients die
ithin the first year after receiving the diagnosis of heart
ailure (1). Further, heart failure consumes a significant
mount of resources, and this is only likely to increase as the
opulation ages. Consequently, the development of thera-
eutic strategies to improve outcomes and slow or halt the
rogression of heart failure is a major goal of clinical cardio-
ascular investigation. Development of successful therapeutic
trategies is predicated on a clear understanding of the patho-
hysiology of heart failure. Although heart failure is a diverse
roup of diseases with numerous etiologies, one common
See page 1883
athophysiological abnormality is perturbation of myocar-
ial energetics, also known as the “energy-depletion” hy-
othesis (2). The alterations in cardiac energy metabolism in
atients with heart failure are extensive and include initially
ncreased glucose utilization followed by reduced glucose
nd fatty acid utilization, decreased production of high
nergy phosphates, reduced oxygen consumption and respi-
atory chain function as well as diminished amounts of
reatine kinase, phosphocreatine, and creatine kinase trans-
er activity (2–11). In contrast, free adenosine diphosphate
ADP) concentration and uncoupling protein activity increase,
oth of which inhibit cardiac function (2,12). These changes
an be detected using phosphorus-31 magnetic resonance
pectroscopy, which shows reduced levels of phosphocre-
tine (PCr), adenosine triphosphate (ATP), and the PCr/
TP ratio in patients with heart failure (2,13,14). Numer-
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merican College of Cardiology. Dr. Eisen receives research support from
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From the Division of Cardiology, Drexel University College of Medicine and
ahnemann University Hospital, Philadelphia, Pennsylvania.us clinical trials have shown the benefits of angiotensin-
onverting enzyme (ACE) inhibitors, angiotensin receptor
lockers, and beta-blockers in improving survival, left ven-
ricular (LV) function, and other parameters in patients
ith heart failure (4,6,7,15,16). These are energy-sparing
herapies. In contrast, energy-consuming therapies such as
he positive inotropes are associated with increased mortal-
ty (17,18). The article by Beer et al. (19) in this issue of the
ournal provides evidence that exercise training may be
nother therapy that improves exercise tolerance and ven-
ricular function and accomplishes this without changes in
igh-energy phosphate concentrations.
Despite the availability of excellent heart failure therapies
ncluding the pharmacologic therapies mentioned in the
receding text, heart failure patients have an annual mor-
ality of 10%, which is even higher for those with more
evere classes of heart failure (20). Therefore, novel thera-
ies, which provide additive benefits to standard heart
ailure therapies, would be highly desirable. Exercise train-
ng has been of considerable interest recently as an adjunc-
ive therapy for patients with heart failure. Some of the
enefits of exercise are noncardiac and include salutary
ffects on peripheral adaptation (21). Other benefits are
ardiac and include improved cardiac function, favorable
ffects on remodeling, and improvements in coronary artery
erfusion (22–25). More compelling, there is evidence that
xercise training may favorably affect outcomes in patients
ith heart failure by reducing hospital readmissions for
ecompensated heart failure and reducing mortality (26–
8). A large clinical trial is underway to evaluate the effect of
xercise training on mortality in patients with heart failure
29). For this therapy to improve survival, it must not be
nergy consuming but should be energy sparing. Another
maging modality, positron emission tomography (PET),
an provide noninvasive insights into myocardial oxygen
etabolism. When myocardial oxygen metabolism is as-
essed by PET in patients with heart failure, there are
triking abnormalities (30). There is evidence that exercise
raining may have beneficial effects on myocardial oxygen
etabolism (31). This would suggest that exercise training
an favorably affect myocardial metabolism in patients with
eart failure, though PET imaging would not provide direct
nformation about myocardial energetics as defined by
igh-energy phosphate concentrations. One approach that
ould provide this information is phosphorus-31 magnetic
esonance spectroscopy.
Phosphorus-31 magnetic resonance spectroscopy has
een the major approach for discerning perturbations in
igh-energy phosphate concentrations as components of
yocardial energetics in patients with heart failure (2,13,
2). In particular, this approach determines the PCr/ATP
atio. In normal myocardium, ATP synthesis outstrips PCr
ynthesis, but when ATP consumption exceeds ATP syn-
hesis, PCr levels decline as PCr is a reservoir of high-
nergy phosphates and can diffuse from the mitochondria to
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May 13, 2008:1892–5 Editorial Commentyocyte myofibrils (2). Myocardial ATP levels remain
table until the very late stages of heart failure (13,33,34). In
rder to maintain ATP levels when ATP consumption
xceeds ATP synthesis, PCr levels fall as high-energy
hosphates are transferred to ADP to form ATP, thus
esulting in a reduction in the PCr/ATP ratio (13,35). In
ddition, the creatine transporter in the mitochondria is
own-regulated in patients with chronic heart failure, re-
ulting in a decline in creatine levels, and this further
epresses the PCr/ATP ratio (36,37). Energy-consumptive
herapies such as positive inotropic agents increase ADP
oncentrations, which inhibit myocardial contractility (12).
he extent of reduction in PCr/ATP ratios correlates with
ew York Heart Association functional class, with greater
eductions in the ratios with more severe classes of heart
ailure (which are defined by the extent of limitations in
xercise tolerance) (32) and with systolic (38) and diastolic
unction (39). A small study of 39 patients with heart failure
nd idiopathic dilated cardiomyopathy showed that the
Cr/ATP ratio as assessed by phosphorus-31 magnetic
esonance spectroscopy may be a more robust predictor of
ardiovascular and all-cause mortality and may be superior
o other predictors of outcomes such as exercise capacity (40).
With this background, the idea of determining the effect
f exercise training on high-energy phosphate concentra-
ions as assessed by phosphorus-31 magnetic resonance
pectroscopy is very timely. In the study by Beer et al. (19),
4 sedentary patients with nonischemic dilated cardiomy-
pathies were randomized to an exercise training group or a
ontrol group. All patients underwent baseline maximal
xercise stress testing, magnetic resonance imaging, and
hosphorus-31 magnetic resonance spectroscopy as well as
ollow-up studies 2 and 8 months later. The exercise
raining group underwent 5 45-min training sessions per
eek for 2 months and were then were encouraged to
ontinue exercise from 2 to 8 months. The control group
eceived no such training. For the exercise group, there was
17% increase in maximal VO2 and a 13% increase in
xercise time. No such improvement was seen in the control
roup. Further, the (LV) ejection fraction was improved and
V dimensions were also seen in the exercise training group
ut not the control group after long-term (8 month) but not
hort-term exercise training. This observation confirmed
he results of other studies (27). Thus, exercise training had
beneficial effect on exercise tolerance, LV function, and
imensions. With regard to myocardial energetics, there
as no significant change in the PCr concentration in
atients in the exercise and in the control groups. Thus,
xercise training did not decrease myocardial energy con-
umption. In fact, there was some evidence that exercise
raining improved LV work power, LV work power/gram
nd LV work power, and forward work efficiency, though
hese differences were not statistically significant. This
as not seen in the control group. Thus, as with ACE
nhibitors and beta-blockers, exercise training can produce smprovements in exercise tolerance and cardiac structure
nd function.
There are issues not addressed by the study of Beer et al.
19). The exact doses of heart failure therapies taken by the
atients was not well defined, so we do not know if these
atients were receiving maximal medical therapy in terms of
CE inhibitor and beta-blocker doses. Whether maximal
herapeutic doses of these agents would improve myocardial
ork efficiency is therefore unknown. Additionally, the
atients enrolled in this study were Weber class A and B
New York Heart Association functional class II) in terms
f their symptoms and thus had relatively preferred exercise
olerance for heart failure patients. Whether the benefits
een in these patients with mild-moderate heart failure in
erms of preserved myocardial energetics can be extrapolated
o patients with more severe heart failure (Weber class C
nd D) is not clear. Not only is it unclear whether these
atients will have improvements in exercise tolerance and
entricular function as a result of exercise training but the
ffect on myocardial energetics in these patients, whose
re-training PCr/ATP ratios are more perturbed than those
nrolled in this study, is also not clear.
The study by Beer et al. (19) provides preliminary
vidence that exercise training in a small group of patients
ith mild to moderate systolic heart failure as defined by
eber class, in addition to its benefits for improving
xercise capacity and LV function, is energy sparing as are
ther therapies associated with improved outcomes such as
CE inhibitors and beta-blockers (4,6,7,15,20). Further
nvestigations in larger groups of patients will be required to
urther clarify the effects of exercise training on myocardial
nergetics. The study by Beer et al. (19) does not appear to
e powered to demonstrate whether exercise training im-
roves forward work efficiency and LV work power, and a
arger study will need to be performed to demonstrate if
xercise training translates into a fundamental improvement
n myocardial work and efficiency. The patient population
as one with well preserved exercise tolerance as they were
eber class A and B. These patients tend to have a better
rognosis. What will be even more crucial will be to
etermine if patients who are Weber class C and D, and
hus have greater limitations to exercise tolerance and worse
utcomes, have similar benefits from exercise training,
ncluding improved exercise tolerance and LV function with
ither no deleterious effect on myocardial energetics or even
mprovement in myocardial work and efficiency. This may
e more easily demonstrated in this patient population as
hey have greater perturbation of high-energy phosphate
oncentrations, including a reduction in myocardial ATP
oncentration in some patients (32). It also may be more
ikely to demonstrate a survival benefit from exercise train-
ng in patients with heart failure who have more severe
unctional limitations and thus have worse outcomes and
ore clinical events. In particular, a larger study involving
atients with more advanced heart failure would be neces-
ary to determine if exercise training has a beneficial effect
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Editorial Comment May 13, 2008:1892–5n survival as well as whether assessments of myocardial
nergetics such as PCr/ATP ratios can predict outcomes in
hese patients. Such a study might also include more
ong-term supervised exercise training beyond the 2-month
eriod in the study by Beer et al. (19). This might more
uccessfully demonstrate a survival benefit for exercise as
ell as improvement in myocardial work and efficiency. As
o whether a larger study might demonstrate salutary effects on
ight ventricular function from exercise training, this may be
ore difficult to predict and to accomplish.
In summary, Beer et al. (19) have provided evidence that
xercise training in patients with Weber class A and B heart
ailure improves exercise performance and ventricular func-
ion without adverse effects on myocardial energetics. This
rovides further justification for exercise training as adjunc-
ive therapy in these patients.
eprint requests and correspondence: Dr. Howard J. Eisen,
ivision of Cardiology, Drexel University College of Medicine
nd Hahnemann University Hospital, 245 North 15th Street,
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